CD8A and COVID-19: This study suggests that, in addition to preexisting cross-reactive memory CD4+ T cells reported previously (10), dissimilar SARS-CoV-2 epitope–specific CD8+ T cell responses could also contribute to divergent COVID-19 clinical outcomes.